Tony Kulesa's guest appearances

Tony Kulesa

The Long Run with Luke Timmerman

BIOS

Thoughts in Between: exploring how technology collides with politics, culture and society

EBRC In Translation

VitaDAO is a community owned collective funding early stage longevity research, governed by $VITA

David Baker

Bob Langer

Chris Garabedian

Andreessen Horowitz

David Kaufman

Steve Graham

Daphne Koller

Jim Collins

Jack Clark

Ben Casnocha

John Evans

David Berry

George Church

Bonnie Anderson

Arvind Gupta

OwlTail

In this episode, we interview Dr. Tony Kulesa, a Principal at the VC firm Pillar. We talk to Tony about his work to open source the biotech company creation process, overrated and underrated investment theses, reading and writing to all the different scales of biology and more!To learn more about founder-led biotech, check out some of Tony's writing on the topic here.For more information about EBRC, visit our website at ebrc.org. If you are interested in getting involved with the EBRC Student and Postdoc Association, fill out a membership application for graduate students and postdocs or for undergraduates and join today!Episode transcripts are the unedited output from Whisper and likely contain errors.

In this episode, we interview <a href="https://www.pillar.vc/team/tony-kulesa/" rel="nofollow" target="_blank">Dr. Tony Kulesa</a>, a Principal at the VC firm Pillar. We talk to Tony about his work to open source the biotech company creation process, overrated and underrated investment theses, reading and writing to all the different scales of biology and more! To learn more about founder-led biotech, check out some of Tony's writing on the topic <a href="https://www.pillar.vc/venture-capital/the-future-of-biotech-is-founder-led/" rel="nofollow" target="_blank">here</a>.For more information about EBRC, visit our website at <a href="http://ebrc.org/" rel="nofollow" target="_blank">ebrc.org</a>. If you are interested in getting involved with the EBRC Student and Postdoc Association, fill out a membership application for <a href="https://ebrc.org/apply-spa/" rel="nofollow" target="_blank">graduate students and postdocs</a> or for <a href="https://docs.google.com/forms/d/e/1FAIpQLSec-RI3RA5ZXfGmwN0dpEK9100EcZG-tfQjBTV9KRVAWEFMuw/viewform" rel="nofollow" target="_blank">undergraduates</a> and join today! Episode transcripts are the unedited output from Whisper and likely contain errors.

22. Funding Founder-Led Biotech w/ Tony Kulesa

Tony Kulesa of Petri.bio on fostering founder-led biotech companies

Ep101: Tony Kulesa on Fostering Founder-Led Biotechs

Tony Kulesa is one of the founders of Petri, a new approach for funding formation stage startups at the intersection of biology and engineering. We spend a lot of this conversation talking about why there is such an explosion of activity in biotech entrepreneurship today and why new models for supporting and financing founders are needed. Regular readers of the Thoughts in Between newsletter may also remember that we recently discussed Tony’s excellent essay on Tyler Cowen’ and talent curation. We jump into this topic towards the end of this episode. -----------------Thanks to Cofruition for consulting on and producing the show. You can learn more about Entrepreneur First at www.joinef.com and subscribe to my weekly newsletter at tib.matthewclifford.com

Tony Kulesa is one of the founders of <a href="https://www.petri.bio/" rel="nofollow" target="_blank">Petri</a>, a new approach for funding formation stage startups at the intersection of biology and engineering. We spend a lot of this conversation talking about why there is such an explosion of activity in biotech entrepreneurship today and why new models for supporting and financing founders are needed. Regular readers of the <a href="http://tib.matthewclifford.com/" rel="nofollow" target="_blank">Thoughts in Between newsletter</a> may also remember that we recently discussed Tony’s <a href="https://kulesa.substack.com/p/tyler-cowen-is-the-best-curator-of" rel="nofollow" target="_blank">excellent essay on Tyler Cowen’ and talent curation</a>. We jump into this topic towards the end of this episode. ----------------- Thanks to <a href="http://cofruition.com/" rel="nofollow" target="_blank">Cofruition</a> for consulting on and producing the show. You can learn more about Entrepreneur First at <a href="http://www.joinef.com/" rel="nofollow" target="_blank">www.joinef.com</a> and subscribe to my weekly newsletter at <a href="http://tib.matthewclifford.com/" rel="nofollow" target="_blank">tib.matthewclifford.com</a>

Tony Kulesa: The founder revolution in biotech

Tony Kulesa is a Co-founder @ Petri, an accelerator in Boston that backs companies developing new biotech applications and technologies in healthcare, food, industrial chemicals, and new materials. Co-founded and funded by Pillar, a venture firm co-founded by the CEOs of Cytyc, Ginkgo Bioworks, Iora Health, and 22 Boston companies, Petri draws on the resources of one of the strongest biotech ecosystems in the world to support founders from around the globe. Dr. Kulesa is an inventor and community builder. Previously, he was the founding Director of the MIT BioMakerspace, a community biology laboratory and incubator space, and an Instructor at the MIT Department of Biological Engineering. He holds a PhD from MIT, where his inventions of new platforms for drug discovery and microbial therapeutics were highlighted in Science Editor’s Choice and Nature Reviews Drug Discovery. While at MIT, he co-founded and directed 3 courses on biotech and entrepreneurship, including BiomedStartup, a course that coaches 10+ teams per year on research commercialization projects. He was a member of the founding officer team at MIT Biotech Group, and an ambassador for Breakout Labs, venture philanthropy from the Thiel Foundation to support companies bringing radical scientific discoveries out of the lab and into the market.Topics:The value of accelerators within the life sciencesVenture creation and innovation within biotech and pharmaEntering the life sciences industry from academia and other industriesThe intersection of technology &amp; biology: Silicon meets Boston &amp; the profile of new funds straddling both philosophies Types of risk within life sciences ventures: technical, biological, marketImpact of Covid-19 on the life sciences industry, both technological and financialInvesting and building in the life sciences revolutionThank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link &amp; license) 

Tony Kulesa is a Co-founder @ <a href="http://petri.bio/" rel="nofollow" target="_blank">Petri</a>, an accelerator in Boston that backs companies developing new biotech applications and technologies in healthcare, food, industrial chemicals, and new materials. Co-founded and funded by Pillar, a venture firm co-founded by the CEOs of Cytyc, Ginkgo Bioworks, Iora Health, and 22 Boston companies, Petri draws on the resources of one of the strongest biotech ecosystems in the world to support founders from around the globe. Dr. Kulesa is an inventor and community builder. Previously, he was the founding Director of the MIT BioMakerspace, a community biology laboratory and incubator space, and an Instructor at the MIT Department of Biological Engineering. He holds a PhD from MIT, where his inventions of new platforms for drug discovery and microbial therapeutics were highlighted in Science Editor’s Choice and Nature Reviews Drug Discovery. While at MIT, he co-founded and directed 3 courses on biotech and entrepreneurship, including BiomedStartup, a course that coaches 10+ teams per year on research commercialization projects. He was a member of the founding officer team at MIT Biotech Group, and an ambassador for Breakout Labs, venture philanthropy from the Thiel Foundation to support companies bringing radical scientific discoveries out of the lab and into the market.Topics:The value of accelerators within the life sciencesVenture creation and innovation within biotech and pharmaEntering the life sciences industry from academia and other industriesThe intersection of technology &amp; biology: Silicon meets Boston &amp; the profile of new funds straddling both philosophies Types of risk within life sciences ventures: technical, biological, marketImpact of Covid-19 on the life sciences industry, both technological and financialInvesting and building in the life sciences revolutionThank you for listening!<a href="https://www.bios.community/" rel="nofollow" target="_blank">BIOS</a> (<a href="https://twitter.com/bios_community" rel="nofollow" target="_blank">@BIOS_Community</a>) unites a community of Life Science innovators dedicated to driving patient impact. <a href="https://www.alix.vc/" rel="nofollow" target="_blank">Alix Ventures</a> (<a href="https://twitter.com/AlixVentures" rel="nofollow" target="_blank">@AlixVentures</a>) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (<a href="https://incompetech.filmmusic.io/song/4985-danger-storm" rel="nofollow" target="_blank">link</a> &amp; <a href="http://creativecommons.org/licenses/by/4.0/" rel="nofollow" target="_blank">license</a>)